ARSA Variants Associated With Cognitive Decline and Long‐Term Preservation of Motor Function in Metachromatic Leukodystrophy
Authors:
- Shanice BeerepootSBShanice Beerepoot
- Daphne H. SchoenmakersDSDaphne H. Schoenmakers
- Francesca FumagalliFFFrancesca Fumagalli
- Samuel GroeschelSGSamuel Groeschel
- Ludger SchölsLudger Schöls
- Raphael SchiffmannRSRaphael Schiffmann
- Odile Boespflug‐TanguyOBOdile Boespflug‐Tanguy
- Caroline SevinCSCaroline Sevin
- Yann NadjarYNYann Nadjar
- Annette BleyABAnnette Bley
- Fanny MochelFMFanny Mochel
Open Access
- 2 August 2025
- journal article
- research article
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 48 (5) , e70072
Abstract
Patients with metachromatic leukodystrophy (MLD) show variable motor and cognitive decline. The ARSA variants c.256C>T, p.(Arg86Trp), c.257G>A, p.(Arg86Gln) and c.542T>G, p.(Ile181Ser) are associated with predominantly cognitive decline. This multinational study analyzed MLD onset type, presenting signs/symptoms, cognitive function, gross motor function, central motor tract involvement, MRI severity score, peripheral neuropathy, and survival of 47 patients (three homozygous for c.256C>T and five, twelve and 27 compound heterozygous for c.256C>T, c.257G>A, or c.542T>G and another ARSA variant, respectively). Eleven underwent hematopoietic stem cell transplantation (HSCT). Onset was late‐juvenile (46.8%) or adult (44.7%) with predominantly cognitive decline ( n = 40/41 symptomatic patients). At diagnosis, untreated patients typically retained independent walking (100%), sparing of central motor tracts (87.5%), and absence of demyelinating neuropathy (95.5%), which persisted in follow‐up for most (76.5%, 71.4%, and 64.7%, respectively). Early‐juvenile onset and rapid motor decline occurred only in patients compound heterozygous for c.256C>T and a severe second variant ( n = 4), showing central motor tract involvement at diagnosis. One untreated and one treated patient died of disease progression, and another from HSCT complications. All other treated patients retained independent walking, and four of five tested normal cognitive function. Median MRI severity score remained lower in treated (13) than untreated patients (25). The phenotype of c.256C>T carriers depends on the severity of the second ARSA variant. Patients harboring c.257G>A or c.542T>G show late‐juvenile or adult onset with cognitive decline and preserved motor function, usually associated with sparing of central motor tracts. In these patients, cognitive function and MRI severity score should be preferred treatment outcomes.Keywords
Funding Information
- Stichting Metakids (2017‐073)
- Fondazione Telethon
- Orchard Therapeutics
- Deutsche Forschungsgemeinschaft (421769743)
- Deutsche Forschungsgemeinschaft (HE8803/1–1)
This publication has 40 references indexed in Scilit:
- Metachromatic leukodystrophy – mutation analysis provides further evidence of genotype–phenotype correlationClinical Genetics, 2008
- Late-onset metachromatic leukodystrophyNeurology, 2006
- Mutations c.459 + 1G > A and p.P426L in the ARSA gene: Prevalence in metachromatic leukodystrophy patients from European countriesMolecular Genetics and Metabolism, 2005
- Motor and psycho-cognitive clinical types in adult metachromatic leukodystrophy: genotype/phenotype relationships?Journal of Physiology-Paris, 2002
- Mutations associated with very late‐onset metachromatic leukodystrophyClinical Genetics, 1999
- Crystal Structure of Human Arylsulfatase A: The Aldehyde Function and the Metal Ion at the Active Site Suggest a Novel Mechanism for Sulfate Ester Hydrolysis,Biochemistry, 1998
- Late-presenting metachromatic leukodystrophyThe Lancet, 1996
- Late juvenile metachromatic leukodystrophy (MLD) in three patients with a similar clinical course and identical mutation on one alleleClinical Genetics, 1996
- Late‐onset metachromatic leukodystrophy: Molecular pathology in two siblingsAnnals of Neurology, 1992
- Two new arylsulfatase A (ARSA) mutations in a juvenile metachromatic leukodystrophy (MLD) patient.1991